ESTRO 2025 - Abstract Book

S1837

Clinical – Upper GI

ESTRO 2025

Keywords: QA in prospective trial, Benchmark-case contouring

References: 1. Weber, D. C., Tomsej, M., Melidis, C., & Hurkmans, C. W. (2012). QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiotherapy and Oncology , 105 (1), 4-8. 2. Baak, R., Willemssen, F. E., van Norden, Y., Eskens, F. A., Milder, M. T., Heijmen, B. J., ... & Méndez Romero, A. (2021). Stereotactic body radiation therapy after chemotherapy for unresectable perihilar cholangiocarcinoma: The strong trial, a phase I safety and feasibility study. Cancers, 13(16), 3991.

3607

Digital Poster Stereotactic body radiotherapy (SBRT) for nonsurgical cholangiocarcinoma.

Jesús Romero Fernandez 1 , Sofia Cordoba Largo 1 , Raquel Benlloch 1 , Antonio Sanchez Ruiz 2 , Mariano Gonzalez Haba 3 , Miguel Pastrana Ledesma 4 , Matias Cea Soriano 5 , Carmen Gonzalez Lois 6 , Joaquin Velasco Jimenez 1 , Irma Zapata Paz 1 , Cristina de la Fuente Alonso 1 , Marta Lopez Valcarcel 1 , Maria Hernandez Miguel 1 , Beatriz Gil Haro 1 , Sofia Santana Jimenez 1 , Sara Perez Mata 1 , Arancha Gallego Barranco 1 , Irene Avila Gomez 1 , Jose Cantillana Barrenas 1 1 Radiation Oncology, Puerta de Hierro Hospital, Madrid, Spain. 2 Medical Oncology, Puerta de Hierro Hospital, Madrid, Spain. 3 Gastroenterology, Puerta de Hierro Hospital, Madrid, Spain. 4 Radiology department, Puerta de Hierro Hospital, Madrid, Spain. 5 Department of General Surgery., Puerta de Hierro Hospital, Madrid, Spain. 6 pathological anatomy department, Puerta de Hierro Hospital, Madrid, Spain Purpose/Objective: To analyze response rate, overall survival (OS), treated-lesion relapse-free survival (TLRFS), hepatic relapse-free survival (HRFS), lymph node metastases-free survival (LNRFS) and distant metastases-free survival (DMFS) after SBRT for unresectable or inoperable cholangiocarcinoma.